Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
2상
완료
NCT02296684
| 대상 질환 | Cancer of Head and Neck, Head and Neck Cancer, Neoplasms, Head and Neck, Carcinoma, Squamous Cell of Head and Neck |
|---|
| 임상 단계 | 2상 |
|---|
| 스폰서 | Washington University School of Medicine |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 67 명 |
|---|
| 중재(약물) | MK-3475 (neoadjuvant), Surgery, Intensity modulated radiation therapy, Image-guided radiation therapy, Cisplatin |
|---|
| 시작일 | 2015년 3월 25일 |
|---|
| 완료일 | 2022년 4월 5일 |
|---|
| 결과 공개일 | 2023년 5월 11일 |
|---|
요약
The goal of this trial is to test the ability of MK-3475 (pembrolizumab) to improve locoregional recurrence and distant metastatic rates in high-risk patients with locally advanced head and neck squamous cell carcinomas (HNSCCs) that are treated with current standard of care surgical approaches.
Locoregional Recurrence Rates in Cohorts 1 and 2
Within 1 year of surgery (surgery occurred within 13-22 days after neoadjuvant MK-3475 dose) · Participants
| Cohort 1: Neoadjuvant MK-3475 and Adjuvant MK-3475 | 2 Participants |
|---|
| Cohort 2: Neoadjuvant MK-3475 | 2 Participants |
|---|
Distant Failure Rate in Cohorts 1 and 2
Within 1 year of surgery (surgery occurred within 13-22 days after neoadjuvant MK-3475 dose) · Participants
| Cohort 1: Neoadjuvant MK-3475 and Adjuvant MK-3475 | 3 Participants |
|---|
| Cohort 2: Neoadjuvant MK-3475 | 1 Participants |
|---|
Rate of Major Pathologic Treatment Effect in Cohort 1
At the time of surgery (surgery occurred within 13-22 days after neoadjuvant MK-3475 dose) · Participants
| Cohort 1: Neoadjuvant MK-3475 and Adjuvant MK-3475 | 20 Participants |
|---|
| Cohort 1: Neoadjuvant MK-3475 and Adjuvant MK-3475 | 8 Participants |
|---|
| Cohort 1: Neoadjuvant MK-3475 and Adjuvant MK-3475 | 8 Participants |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.